BRIEF-Ideaya Biosciences Announces First-Patient-In For Phase 1 Trial Of IDE892

Reuters03-09 19:03

March 9 (Reuters) - IDEAYA Biosciences Inc IDYA.O:

IDEAYA BIOSCIENCES ANNOUNCES FIRST-PATIENT-IN FOR PHASE 1 TRIAL OF IDE892, A POTENTIAL BEST-IN-CLASS PRMT5 INHIBITOR FOR MTAP-DELETED SOLID TUMORS, AND PROVIDES MTAP AND CDKN2A PIPELINE UPDATE
IDEAYA BIOSCIENCES INC - IDE892 TO BE COMBINED WITH IDE397 IN PHASE 1 TRIAL IN MID-2026
IDEAYA BIOSCIENCES INC - TARGETS CDKN2A DEVELOPMENT CANDIDATE NOMINATION IN H2 2026 AND IND IN H1 2027

Source text: ID:nPn2MrNyga

Further company coverage: IDYA.O

((Reuters.Briefs@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2618640402?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-09 19:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618640402","market":"fut","top_or_hot":-1,"title":"BRIEF-Ideaya Biosciences Announces First-Patient-In For Phase 1 Trial Of IDE892","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Ideaya Biosciences Announces First-Patient-In For Phase 1 Trial Of IDE892</title></head><body><p><span>March 9 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/IDYA\">IDEAYA Biosciences</a> Inc <span>IDYA.O</span>:</p><ul><li><p>IDEAYA BIOSCIENCES ANNOUNCES FIRST-PATIENT-IN FOR PHASE 1 TRIAL OF IDE892, A POTENTIAL BEST-IN-CLASS PRMT5 INHIBITOR FOR MTAP-DELETED SOLID TUMORS, AND PROVIDES MTAP AND CDKN2A PIPELINE UPDATE</p></li><li><p>IDEAYA BIOSCIENCES INC - IDE892 TO BE COMBINED WITH IDE397 IN PHASE 1 TRIAL IN MID-2026</p></li><li><p>IDEAYA BIOSCIENCES INC - TARGETS CDKN2A DEVELOPMENT CANDIDATE NOMINATION IN H2 2026 AND IND IN H1 2027</p></li></ul><p>Source text: <span>ID:nPn2MrNyga</span></p><p>Further company coverage: <span>IDYA.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Ideaya Biosciences Announces First-Patient-In For Phase 1 Trial Of IDE892</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Ideaya Biosciences Announces First-Patient-In For Phase 1 Trial Of IDE892\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-09 19:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Ideaya Biosciences Announces First-Patient-In For Phase 1 Trial Of IDE892</title></head><body><p><span>March 9 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/IDYA\">IDEAYA Biosciences</a> Inc <span>IDYA.O</span>:</p><ul><li><p>IDEAYA BIOSCIENCES ANNOUNCES FIRST-PATIENT-IN FOR PHASE 1 TRIAL OF IDE892, A POTENTIAL BEST-IN-CLASS PRMT5 INHIBITOR FOR MTAP-DELETED SOLID TUMORS, AND PROVIDES MTAP AND CDKN2A PIPELINE UPDATE</p></li><li><p>IDEAYA BIOSCIENCES INC - IDE892 TO BE COMBINED WITH IDE397 IN PHASE 1 TRIAL IN MID-2026</p></li><li><p>IDEAYA BIOSCIENCES INC - TARGETS CDKN2A DEVELOPMENT CANDIDATE NOMINATION IN H2 2026 AND IND IN H1 2027</p></li></ul><p>Source text: <span>ID:nPn2MrNyga</span></p><p>Further company coverage: <span>IDYA.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nTUA85JPPR:1","article_id":"2618640402","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618640402","pubTimestamp":1773054225,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Ideaya Biosciences Announces First-Patient-In For Phase 1 Trial Of IDE892March 9 (Reuters) - IDEAYA Biosciences Inc IDYA.O:IDEAYA BIOSCIENCES ANNOUNCES FIRST-PATIENT-IN FOR PHASE 1 TRIAL OF IDE8","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IDYA":"IDEAYA Biosciences"},"translate_title":"简介-Ideaya Biosciences宣布IDE892 1期试验的首例患者","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IDYA":0.9},"content_text":"BRIEF-Ideaya Biosciences Announces First-Patient-In For Phase 1 Trial Of IDE892March 9 (Reuters) - IDEAYA Biosciences Inc IDYA.O:IDEAYA BIOSCIENCES ANNOUNCES FIRST-PATIENT-IN FOR PHASE 1 TRIAL OF IDE892, A POTENTIAL BEST-IN-CLASS PRMT5 INHIBITOR FOR MTAP-DELETED SOLID TUMORS, AND PROVIDES MTAP AND CDKN2A PIPELINE UPDATEIDEAYA BIOSCIENCES INC - IDE892 TO BE COMBINED WITH IDE397 IN PHASE 1 TRIAL IN MID-2026IDEAYA BIOSCIENCES INC - TARGETS CDKN2A DEVELOPMENT CANDIDATE NOMINATION IN H2 2026 AND IND IN H1 2027Source text: ID:nPn2MrNygaFurther company coverage: IDYA.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618640402","isCrawlerRequest":true}